Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Clinical Trial

Official title:

A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03414034
• Other study ID #: TROV-053
• Secondary ID: U1111-1208-1579
• Status: Completed
• Phase: Phase 2
• Start date: June 18, 2018
• Est. completion date: October 16, 2023

Study information

• Verified date: October 2023
• Source: Cardiff Oncology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: October 16, 2023
• Est. primary completion date: October 16, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males = 18 years of age on the day of consenting to the study.

2. Ability to swallow the study drug as a whole tablet.

3. Histologically confirmed prostate adenocarcinoma without significant small- cell/neuroendocrine or other variant histologies, with rising PSA and/or radiographic progression in the setting of castration-level testosterone (< 50 ng/dL) indicating mCRPC. Participants must have either undergone surgical castration or continue on GnRH agonist/antagonist on the appropriate schedule throughout the study period.

4. Asymptomatic or minimally symptomatic disease.

5. Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any time (past or present).

6. Participant currently receiving abiraterone and prednisone for CRPC.

7. Participant has been on abiraterone for castration-sensitive prostate cancer (CSPC) or castration-resistant prostate cancer (CRPC). Participants who have received abiraterone for CSPC must have had a response to hormonal therapy, as defined by any decline in PSA, radiographic response and/or clinical benefit after starting hormonal therapy.

Participants who have received abiraterone for CRPC must have responded to abiraterone, defined by any decline in PSA, radiographic response, and/or clinical benefit after starting abiraterone.

8. Two rising PSA values separated by at least 1 week, one showing a rise of at least 0.3 ng/mL and one confirmatory value not showing a decline, while on abiraterone therapy.

9. Eastern Cooperative Oncology Group (ECOG) performance status = 1

10. Participant has adequate bone marrow and organ function as shown by:

• Absolute neutrophil count (ANC) = 1.0 x 109/L

• Platelets = 100 x 10^9/L

• Hemoglobin (Hgb) = 9.0 g/dL

• Serum creatinine = 2 x the upper limit of normal (ULN)

• Total serum bilirubin = 1.5 x ULN (in participants with known Gilbert Syndrome, a total bilirubin = 3.0 x ULN, with direct bilirubin = 1.5 x ULN)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 x ULN (or = 5.0 x ULN if hepatic metastases are present)

Exclusion Criteria:

1. Major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.

2. Rapidly progressive symptoms of mCRPC.

3. Acute neurological dysfunction as a result of bone metastasis.

4. Previously treated with enzalutamide or experimental therapies directed against androgen receptor (ie, apalutamide).

5. Use of any chemotherapy, investigational agents, immunotherapy, or hormonal therapy other than GnRH agonists within 28 days of the start of treatment on protocol.

Use of bone targeted agents including bisphosphonates and RANK ligand inhibitors is allowed if on stable dose; Xgeva or Zometa cannot be started within 28 days of initiating study therapy.

6. Systemic corticosteroids except as part of on label treatment prostate cancer regimens. Note: Topical applications (eg, rash), inhaled sprays (eg, obstructive airways diseases), eye drops or local injections (eg, intra-articular) are allowed.

7. Treatment with any of the drugs listed in Section 8.4.5 at the time of study treatment initiation.

8. Has received wide field radiotherapy (including therapeutic radioisotopes such as radium 223) = 28 days or limited field radiation for palliation = 14 days prior to starting study drug or has not recovered from side effects of such therapy.

9. New York Heart Association (NYHA) Class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition, or hypertensive or metabolic condition.

10. Myocardial infarction in the previous 12 weeks (from the start of treatment)

11. QT interval with Fridericia's correction [QTcF] >470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of potentially correctible causes of QT prolongation (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during screening and that result may be used to determine eligibility.

12. Planned concomitant use of medications known to prolong the QT/QTc interval

13. Presence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.

Related Conditions & MeSH terms

• Metastatic Castration-Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Onvansertib
Onvansertib orally
• Abiraterone
Abiraterone orally
• Prednisone
Prednisone orally

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Cardiff Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks		Week 12
Secondary	Percentage Change from Baseline in PSA at 12 Weeks		Baseline and Week 12
Secondary	Maximal Percentage Change from Baseline in PSA		Baseline up to 20 months
Secondary	Absolute Change from Baseline in PSA Response		Baseline up to 20 months
Secondary	Time to PSA Progression per PCWG3 criteria		Baseline up to 20 months
Secondary	Time to Radiographic Progression per PCWG3 criteria		Baseline up to 20 months
Secondary	Radiographic Response per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)		Baseline up to 20 months
Secondary	Percentage of Participants Who are Adherent to Study Treatment (Per-Protocol Analysis) With Lack of Prostate-specific Antigen (PSA) Progression per Prostate Cancer Working Group 3 (PCWG3) Criteria After 12 Weeks		Week 12
Secondary	Number of Participants With Adverse Events per Common Terminology Criteria for Adverse Events (CTCAE)		Baseline up to 30 days after last dose of study drug (Up to 20 months)
Secondary	Number of Participants With Dose Limiting Toxicity (DLT)	DLT is defined as a hematologic adverse event (AE) of Grade = 3 or nonhematologic AE of Grade = 3 considered related to the study drug(s).	Up to 20 months